ArticleJAMA network open2026
A Multicomponent Strategy to Increase Human Papillomavirus Vaccination Rates in Primary Care: A Cluster Randomized Clinical Trial.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04180462 (Randomized Controlled Trial to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Importance: Human papillomavirus (HPV) vaccination prevents multiple cancers, yet vaccination rates by the recommended age remain well below national goals. Objective: To evaluate the effectiveness of a multicomponent strategy in increasing HPV vaccination rates in primary care settings by 13 years of age. Design, Setting, and Participants: This cluster randomized clinical trial with a parallel-group design and 1:1 allocation was conducted at 20 pediatrics primary care practices from a practice-based research network in the St Louis, Missouri, metropolitan area by clinicians delivering routine well-child visits within participating practices. The intervention was implemented over 24 months (July 1, 2020, to September 30, 2022) with follow-up at 36 months (July 1, 2022, to September 30, 2023; 12 months after the intervention). Baseline characteristics were assessed using 2019 data. Interventions: (1) Practice facilitation by a trained external facilitator, (2) audit and feedback of HPV vaccination rates, (3) HPV vaccination education, and (4) announcement-style communication strategy. Main Outcomes and Measures: The primary outcomes were the proportion of patients who received the first HPV vaccine (initiation) and completed the series (completion) by 13 years of age, assessed at 24 months. Enduring effect was assessed at 36 months. Data were analyzed based on the intention-to-treat principle. Results: A total of 86 clinicians participated (40 control and 46 intervention; 65 women [75.6%]). Most were physicians (67 [77.9%]) and median time in practice was 18 years (IQR, 10-24 years). The intervention group had a higher percentage of privately insured patients than the control group (1562 of 1727 [90.4%] vs 717 of 1371 [52.3%]). At 24 months, HPV vaccination initiation rates were 80.1% (1723 of 2151) in the intervention group vs 75.5% (1219 of 1615) in the control group; completion rates were 52.8% (1135 of 2151) in the intervention group vs 50.1% (809 of 1615) in the control group. At 36 months, initiation rates were 82.0% (1812 of 2211) in the intervention group vs 74.6% (1052 of 1410) in the control group; completion rates were 57.8% (1279 of 2211) in the intervention group vs 49.9% (703 of 1410) in the control group. Fully adjusted models showed no differences for vaccination initiation (24 months: odds ratio [OR], 1.15 [95% CI, 0.78-1.70]; 36 months: OR, 1.42 [95% CI, 0.96-2.11]) or completion (24 months: OR, 0.96 [95% CI, 0.72-1.29]; 36 months: OR, 1.24 [95% CI, 0.92-1.67]), although intervention effects for initiation increased significantly over time (P = .04). Conclusions and Relevance: In this cluster randomized clinical trial of a multicomponent intervention in 20 practices, HPV vaccination rates by 13 years of age were not significantly different between groups, although intervention effects increased significantly over time for initiation of vaccination. System-focused interventions may require extended evaluation periods to demonstrate measurable improvements. Trial Registration: ClinicalTrials.gov Identifier: NCT04180462.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.